Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, announced that CEO Mike Andriole will join a fireside chat at the Jefferies Global Healthcare Conference.
Rhea-AI Summary
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing medicines for deadly diseases, announced that CEO Mike Andriole will join a fireside chat at the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 3:00 p.m. ET. An audio webcast will be available on Chimerix's Investor Relations website and archived for 90 days.
Positive
- Participation in Jefferies Global Healthcare Conference could increase visibility among investors.
- Potential to attract new investors and partnerships through the conference.
Negative
- No mention of new product launches or major clinical trial updates in the PR.
- immediate impact on stock price without substantial new information.
Details
News Market Reaction – CMRX
The recorded move for CMRX in the trading session of this news was +4.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACT:
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.